Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
Largest Facility in Nordics for Clinical Supply of Cell Therapies
SÖDERTALJE, SWEDEN, 4 January 2024 – Anocca AB, a leading TCR-T[1] cell therapy company, today announced it has received a certificate of good manufacturing practice (GMP) compliance from the Swedish Medical Product Agency for its in-house cell therapy manufacturing facility.